PDCD1 and melanoma: In a phase I/II study, in patients with advanced melanoma who failed to respond to anti-PD-1 therapy, the combination therapy of relatlimab and nivolumab showed a satisfying tolerance with an objective response rate (ORR) of 11.5% (65).The combination of anti-LAG3 and anti-PI3Kδ antibodies has a therapeutic potential to restrict tumor burden, and the results show that the anti-LAG3 mAb exerts its effects within tumors (66, 67).